Everything below concerns fatty diacid. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Clinical research programs have evaluated tirzepatide in adults with type 2 diabetes and in adults with obesity or excess weight. Trials generally reported reductions in glycated hemoglobin and body weight across treatment periods of several months. Since these studies enrolled defined populations under controlled conditions, the findings describe group averages rather than individual outcomes. Open questions include the durability of effects after treatment stops, variation among subgroups, and the long-term consequences of sustained dual receptor stimulation. Published trial summaries should be consulted for exact measurements rather than secondary accounts.
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its backbone derives from the native glucose-dependent insulinotropic polypeptide sequence, altered at several positions to resist enzymatic cleavage. A fatty diacid group attached through a linker extends plasma residence time by promoting reversible binding to serum albumin. The molecule carries a net negative charge near physiological pH and has a reported molecular weight close to 4813 daltons. These features separate it from shorter incretin analogs and account for its prolonged dosing interval.
Pharmacologically, tirzepatide activates two distinct G protein-coupled receptors: the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Binding at each target triggers cyclic AMP accumulation and downstream signaling in pancreatic beta cells, adipose tissue and the central nervous system. Because the two pathways overlap only partially, the combined effect on insulin secretion, glucagon suppression and appetite signaling differs from that of selective single-receptor compounds. Affinity is not equal across the two targets, and the clinical meaning of that imbalance remains an area of active study.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Includes the 39-residue backbone and the attached fatty diacid |
| Molecular weight | Approximately 4813 Da | Average mass; the monoisotopic value is slightly lower |
| Receptor targets | GIP receptor and GLP-1 receptor | Dual engagement defines the pharmacological class |
| Backbone length | 39 amino acids | Sequence modified from native glucose-dependent insulinotropic polypeptide |
| Albumin interaction | Reversible, mediated by the fatty diacid | Slows renal clearance and lengthens circulation time |
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
== Pharmacodynamics == Cinnarizine is classified as a selective antagonist of T-type voltage-operated calcium ion channels, because its binding blocks the channels and keeps them inert. It has a Ki (inhibitory constant) value of 22 nM. It is also known to have antihistaminic, antiserotoninergic and antidopaminergic effects, binding to H1 histamine receptors, and dopaminergic (D2) receptors. The IC50 (half-maximal inhibitory concentration) of cinnarizine for smooth muscle contraction inhibition is 60 mM and it has been shown that this drug preferentially binds to its target calcium channels when they are in an open, as opposed to closed conformation. In treatment of nausea and motion sickness it was previously hypothesized that cinnarizine exerts its effects by inhibiting the calcium currents in voltage gated channels in type II vestibular hair cells within the inner ear. However, more recent evidence supports the idea that at pharmacologically relevant levels (0.3–0.5 μM), cinnarizine is not lessening vestibular vertigo by blocking calcium channels, but rather by inhibiting potassium (K+) currents that are activated by heightened hydrostatic pressure on the hair cells. It is true that cinnarizine does abolish calcium currents in vestibular hair cells as well; it is just that this only occurs at higher concentrations of drug (3 μM). The inhibition of these currents works to lessen the vertigo and motion-induced nausea by dampening the over-reactivity of the vestibular hair cells, which send information about balance and motion to the brain.
For example, a reactivity ratio that is less than one for component 1 indicates that this component reacts with the other type of monomer more readily. Given this information, which is available for a multitude of monomer combinations in the "Wiley Database of Polymer Properties", the Mayo-Lewis equation can be used to predict the composition of the polymer product for all initial mole fractions of monomer. This equation is derived using the Markov model, which only considers the last segment added as affecting the kinetics of the next addition; the Penultimate Model considers the second-to-last segment as well, but is more complicated than is required for most systems. When both reactivity ratios are less than one, there is an azeotropic point in the Mayo-Lewis plot. At this point, the mole fraction of monomer equals the composition of the component in the polymer. There are several ways to synthesize random copolymers. The most common synthesis method is free radical polymerization; this is especially useful when the desired properties rely on the composition of the copolymer rather than the molecular weight, since free radical polymerization produces relatively disperse polymer chains. Free radical polymerization is less expensive than other methods, and produces high-molecular weight polymer quickly. Several methods offer better control over dispersity. Anionic polymerization can be used to create random copolymers, but with several caveats: if carbanions of the two components do not have the same stability, only one of the species will add to the other.
Kidder had a central supporting role in the airplane-themed drama The Great Waldo Pepper (1975) opposite Robert Redford and Susan Sarandon, followed by a lead role in the psychological horror film The Reincarnation of Peter Proud, directed by J. Lee Thompson, in which she portrayed a woman about whom a college professor has recurring nightmares. Variety praised her performance in the latter film as "outstandingly rich." In the summer of 1975, Kidder was hired to direct a documentary short chronicling the making of The Missouri Breaks (1976), a Western film starring Marlon Brando and Jack Nicholson. "I was such a jerk," she recalled. "I mean, I thought they wanted a real documentary. So, I filmed all the behind-the-scenes rows and arguments and shot footage of the vet shooting up the horses with tranquilizers so the actors would look as if they rode well. What an idiot I was. Then when they fired me, I realized what they'd wanted was a publicity film." She subsequently co-starred with Peter Fonda in 92 in the Shade, also in 1975, a drama directed by novelist Thomas McGuane, based on his own book. Kidder then took a hiatus from acting, though she appeared in the March 9, 1975, edition of The American Sportsman, learning how to hang glide, and providing the narration, with a remote microphone recording her reactions in flight; the segment concluded with Kidder doing solos soaring amid the Wyoming Rockies. She was also photographed by Douglas Kirkland for the March 1975 issue of Playboy, accompanied by an article written by Kidder herself.
Endocrine: Impotence, increased or decreased libido: gynecomastia in the male; breast enlargement and galactorrhea in the female; testicular swelling; elevation or depression of blood sugar levels. Other: Jaundice (simulating obstructive); altered liver function; parotid swelling; alopecia; flushing; weight gain or loss; urinary frequency, nocturia; perspiration.
Sources: en.wikipedia.org
He looked pale, delicate and shaky, not his usual robust self: "He was very ill when he got here." After being taken by Reitell to check in at the Chelsea Hotel, Thomas took the first rehearsal of Under Milk Wood. They then went to the White Horse Tavern in Greenwich Village, before returning to the Chelsea Hotel. The next day, Reitell invited him to her apartment, but he declined. They went sightseeing, but Thomas felt unwell and retired to his bed for the rest of the afternoon. Reitell gave him half a grain (32.4 milligrams) of phenobarbitone to help him sleep and spent the night at the hotel with him. Two days later, on 23 October, at the third rehearsal, Thomas said he was too ill to take part, but he struggled on, shivering and burning with fever, before collapsing on the stage. The following day, 24 October, Reitell took Thomas to see her doctor, Milton Feltenstein, who administered cortisone injections and Thomas made it through the first performance that evening, but collapsed immediately afterwards. "This circus out there," he told a friend who had come back-stage, "has taken the life out of me for now." Reitell later said that Feltenstein was "rather a wild doctor who thought injections would cure anything."
Other traditional triglyceride lipases (EC 3.1.1.3) include Lipase member N, DDHD2, PNLIPRP3, PNPLA4, and PNPLA5. In addition, there are various other non-traditional lipases including Monoacylglycerol lipases (eg: MGLL, ABHD2, and ABHD6), and Diacylglycerol lipases (eg: DAGLA, DAGLB, and ABHD11). Not all lipase-family proteins function as lipases in humans. Some like Lipase member H and Lipase member I function as phospholipases, while others like pancreatic lipase related protein 1 (PNLIPRP1), LIPJ, LIPK, and LIPM do not (yet) have a well established function as an enzyme.
=== CBRN equipment === Light Anti-Gas Respirator - Issued until the arrival of the S6 respirator. S6 NBC Respirator - Issued from 1966 S10 NBC Respirator - Issued from 1986 No. 1 Mk 1-4 Protective Suit
Major (Acting Lieutenant Colonel) Graham Evan William Tudor Raikes (510624), Adjutant General's Corps (SPS). 24565384 Warrant Officer Class 2 John Joseph Richards, Adjutant General's Corps (RMP). W0801011 Staff Sergeant Sandra Robson, The Royal Logistic Corps. Major Philip James Francois Schofield (495231), The Royal Green Jackets. Major Michael Peter Shapland (504505), Royal Tank Regiment. Major Alistair Colin Sheppard (508235), Corps of Royal Engineers. Acting Lieutenant Colonel Robin Fitzroy Somerset (414981), Winchester College Combined Cadet Force, Territorial Army. 24386268 Warrant Officer Class 2 Kevin Stewart, Royal Regiment of Artillery. Captain John Sutherland (537667), The Highlanders. Major Leslie Harris-Ward, , (502300), The Parachute Regiment (Volunteers), Territorial Army. Major Robert William Warren (513382), Adjutant General's Corps (RMP). Overseas Award Lieutenant Wong Hon Wing (538568), General List. Royal Air Force Flight Sergeant Ronald John Bennett (D8011572). Flight Lieutenant Ian Michael Beresford (8151887). Warrant Officer George Arthur Biddleston (D8068720). Sergeant Karl Richard Brown (D8126056). Flight Lieutenant (now Squadron Leader) Stephen John Butler (8080431). Squadron Leader Sean Chiddention (8028456). Flight Lieutenant Andrew Cubin (8027993). Flight Lieutenant Neil Cummings (3145881), Royal Air Force Volunteer Reserve (Training). Corporal Anthony David Deacon (R8198216). Squadron Leader Brian Dean (4278701), (Retired). Junior Technician Peter Doherty (E8254300). Corporal Christine Doyley (E8233551).
Regardless of their mechanism, the menstrual disturbances associated with spironolactone can usually be controlled well by concomitant treatment with a birth-control pill, due to the progestin component.
Sources: en.wikipedia.org
It is a synthetic peptide that activates both the GIP and GLP-1 receptors, making it a dual agonist. Approved products are given by injection rather than by mouth. It is not a small molecule and does not belong to the older sulfonylurea or thiazolidinedione families.
Engaging two receptors recruits signaling pathways that only partly coincide. This can shift the magnitude of effects on insulin release, glucagon levels and appetite relative to selective agents. Whether the pairing delivers benefits beyond a simple sum of the two is still debated in the literature.
The proportional contribution of each receptor to observed clinical effects has not been fully separated. Long-term consequences of continuous dual stimulation are likewise unclear. Investigators continue to probe these points through laboratory and clinical work.
It is a synthetic peptide and a dual agonist of two incretin receptors. It is not a small molecule, and it is not structurally related to the older single-receptor peptide agonists.